usdaed

Alibaba, in the last decade, was a monument to ambition. It rose swiftly, a digital empire built on the backs of countless delivery drivers, warehouse workers, and small merchants. Then came the reckoning. The founder, a man who dared speak his mind, vanished. A silence descended, heavier than any decree. The whispers started: scrutiny, delisting threats, audits… a slow strangulation of trust. It wasn’t just about numbers; it was about control. And those who control the flow of goods, control much more.

As of the reporting period, QV Investors’ largest holdings include:

Grand View Research, a firm whose pronouncements I regard with the same cautious amusement I reserve for fortune tellers, estimates a market of $3.5 trillion by 2033. A sum, naturally, presented with the confident air of someone who’s misplaced a decimal point. The implication – that we’re in the ‘early stages’ – is, of course, the standard incantation before any speculative bubble. Against this backdrop of orchestrated optimism, a few companies, momentarily less obscured by the hype, warrant a fleeting, skeptical glance.

Whilst putting all one’s eggs in a single basket is, of course, a frightfully risky proposition – akin to wagering the family silver on a particularly unreliable racehorse – history does suggest that such ventures can, on occasion, bear fruit. A modest ten thousand dollars invested in Nvidia back in 2015, for instance, would have blossomed into a positively staggering $3.7 million. Similar strokes of good fortune were to be had with Advanced Micro Devices and Broadcom, yielding a handsome $800,000 and $340,000 respectively. Not to be sneezed at, what!

One hears whispers, of course, that the current market wobble is connected to a rather ambitious, and some might say quixotic, attempt by the United States to acquire Greenland. A most peculiar business, that, but it seems to have rattled a few cages. However, Micron, bless its silicon heart, appears to be immune to such geopolitical shenanigans, largely due to a rather clever bit of positioning in the artificial intelligence (AI) chip market. It’s a jolly good thing, too, as a gloomy stock market is rarely conducive to a pleasant afternoon tea.

The whispers now speak of a different current, a challenge not from the expected rivals—AMD, Broadcom, the usual parade of giants—but from a more unassuming source. A place where the work is less about flash and more about the steady accumulation of value.

Recent pronouncements from the political sphere – a temporary cap on credit card interest rates – have caused a ripple of unease amongst shareholders of American Express. A surface disturbance, perhaps, but one that exposes the fragility inherent in any system reliant on regulatory forbearance. The President’s declaration, while potentially lacking firm legal grounding, functions as a stark reminder: no privilege is absolute, no arrangement impervious to the shifting winds of public sentiment. The initial reaction – a selling of shares – was predictable, a flight from perceived risk. It revealed a disheartening lack of perspective, a tendency to equate short-term volatility with fundamental weakness.

Mr. Michael Saylor, of Strategy, a gentleman who has devoted himself with remarkable zeal to the cause of Bitcoin, and indeed steered his company towards a most substantial investment in the same, remains, however, undeterred. He confidently predicts a further increase, not merely substantial, but approaching the astonishing figure of $1,000,000. One cannot help but observe that such a prediction, while displaying a commendable degree of optimism, might be considered, by the more cautious observer, a trifle extravagant.

The central character in this tale is VK2735, a dual GLP-1/GIP agonist. Now, I’m not a biochemist, and frankly, the explanations usually involve diagrams that look like the schematics for a small nuclear reactor. But essentially, it’s a drug designed to tackle diabetes and, more lucratively, obesity. It enters a crowded field, competing with the established giants – Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound – which have already demonstrated a knack for helping people shed pounds, and, incidentally, for generating substantial revenue.